TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34352143

Group type: EXPERIMENTAL
Intervention: Irrigation-brush-irrigation (test) with chlorhexidine (0.2%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Repeated irrigation alone (control)
Number of subjects: 20
Study: 34352165

Group type: EXPERIMENTAL
Intervention: Second-Generation Antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34352166

Group type: EXPERIMENTAL
Intervention: Amyloid Burden
Number of subjects: 0
Study: 34352386

Group type: EXPERIMENTAL
Intervention: Health coach-delivered single session + portal-like messaging via web portal over 30 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health coach-delivered single session + enhanced usual care (EUC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) + portal-like messaging via web portal over 30 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) + enhanced usual care (EUC)
Number of subjects: 0
Study: 34352736

Group type: EXPERIMENTAL
Intervention: Intracortical microelectrode array
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34352834

Group type: EXPERIMENTAL
Intervention: Rapid ART initiation (within 7 days of HIV diagnosis)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard ART initiation (not specifically defined, but initiated as soon as possible)
Number of subjects: 350
Study: 34352924

Group type: EXPERIMENTAL
Intervention: Retosiban
Number of subjects: 98

Group type: COMPARATOR
Intervention: Comparator (placebo/atosiban)
Number of subjects: 98
Study: 34352935

Group type: EXPERIMENTAL
Intervention: Poloxamer-based thermosensitive sol-gel (PTAS) agent applied to the operative field after ALND
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no poloxamer applied)
Number of subjects: 170
Study: 34353122

Group type: EXPERIMENTAL
Intervention: SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34353317

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 186
Study: 34353599

Group type: EXPERIMENTAL
Intervention: Angio-IMR >40 U
Number of subjects: 340

Group type: COMPARATOR
Intervention: Angio-IMR ≤40 U
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Angio-IMR
Number of subjects: 340
Study: 34353802

Group type: EXPERIMENTAL
Intervention: PCT-guided group
Number of subjects: 500

Group type: COMPARATOR
Intervention: GOLD guideline-guided group
Number of subjects: 500
Study: 34353808

Group type: EXPERIMENTAL
Intervention: Cloxacillin 2 g/4-hour intravenous plus fosfomycin 3 g/6-hour intravenous for 7 days
Number of subjects: 183

Group type: COMPARATOR
Intervention: Cloxacillin 2 g/4-hour intravenous alone for 7 days
Number of subjects: 183
Study: 34353822

Group type: EXPERIMENTAL
Intervention: High-definition upper gastrointestinal (GI) endoscopy without magnification
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 153
Study: 34353848

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 137
Study: 34353986

Group type: EXPERIMENTAL
Intervention: Permanent hypoparathyroidism
Number of subjects: 141
Study: 34354225

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T) at 0.3 mg/kg every 6 weeks for two cycles
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T) at 0.3 mg/kg every 6 weeks
Number of subjects: 200
Study: 34354626

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34354735

Group type: EXPERIMENTAL
Intervention: Diagnostic protocol including multiple ligation-dependent probe amplification for copy number variation (CNV) detection
Number of subjects: 67
Study: 34354920

Group type: EXPERIMENTAL
Intervention: Tafasitamab (TAFA) plus lenalidomide (LEN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Number of subjects: 0
Study: 34355001

Group type: EXPERIMENTAL
Intervention: Positive End-Expiratory Pressure (PEEP) strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 34355155

Group type: EXPERIMENTAL
Intervention: 16 g/day of inulin (prebiotic) supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Maltodextrin (placebo) supplementation
Number of subjects: 48
Study: 34355278

Group type: EXPERIMENTAL
Intervention: Maternal SARS-CoV-2 infection during pregnancy
Number of subjects: 56

Group type: COMPARATOR
Intervention: History of SARS-CoV-2 infection prior to gestational week 12
Number of subjects: 56
Study: 34355282

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study: 34355354

Group type: EXPERIMENTAL
Intervention: Inotersen (continuous weekly treatment)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (switched to inotersen at OLE study baseline)
Number of subjects: 135
Study: 34355741

Group type: EXPERIMENTAL
Intervention: Presence of PD-L1(+) circulating tumor cells (CTCs) detected with CellSearch® system
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Presence of PD-L1(+) CTCs
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Absence of gene alterations, number of metastatic sites, prior systemic therapies, presence of CTCs and PD-L1(+) CTCs
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Squamous cell carcinoma histology, number of prior systemic treatments, presence of CTC
Number of subjects: 54

Group type: COMPARATOR
Intervention: PD-L1 expression in tumor tissue
Number of subjects: 54
Study: 34356039

Group type: EXPERIMENTAL
Intervention: Confirmed sarcopenia (LMM adjusted for BMI)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Probable sarcopenia
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Confirmed sarcopenia (LMM adjusted for height2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Age in patients with probable sarcopenia
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Stroke duration in patients with probable or confirmed sarcopenia
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L scores in patients with confirmed sarcopenia
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Stroke duration as a factor for confirmed sarcopenia
Number of subjects: 81
Study: 34356046

Group type: EXPERIMENTAL
Intervention: Genome-wide SNP-level analysis in patients with 22q11.2DS
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Genome-wide SNP-level analysis in patients without 22q11.2DS
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gene-level analysis in patients with 22q11.2DS
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gene-level analysis in patients without 22q11.2DS
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gene set analysis in patients with 22q11.2DS
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gene set analysis in patients without 22q11.2DS
Number of subjects: 5
Study: 34357432

Group type: EXPERIMENTAL
Intervention: Pre-operative oxygen saturation measured by laser-Doppler spectrophotometry
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pre-operative minimal value of oxygen saturation
Number of subjects: 34
Study: 34357478

Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Positive fluid balance
Number of subjects: 313

Group type: COMPARATOR
Intervention: AKI patients
Number of subjects: 313

Group type: COMPARATOR
Intervention: Dialysis dependence
Number of subjects: 313

Group type: COMPARATOR
Intervention: Renal recovery
Number of subjects: 313

Group type: COMPARATOR
Intervention: Chronic kidney disease (CKD)
Number of subjects: 313
Study: 34357561

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (once-daily)
Number of subjects: 2989

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2989
Study: 34357785

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34357790

Group type: EXPERIMENTAL
Intervention: Teaching Kitchen Medical Groups Visit with an eHealth Platform
Number of subjects: 0
Study: 34358399

Group type: EXPERIMENTAL
Intervention: Rapid blood test combining GFAP and UCH-L1 measurements
Number of subjects: 1918
Study: 34358484

Group type: EXPERIMENTAL
Intervention: Infigratinib 125 mg orally once daily for 21 days of 28-day cycles until disease progression, intolerance, withdrawal of consent, or death.
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Infigratinib
Number of subjects: 108
Study: 34358493

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34358495

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34358835

Group type: EXPERIMENTAL
Intervention: ALS patients
Number of subjects: 26
Study: 34358839

Group type: EXPERIMENTAL
Intervention: Gastrointestinal Dysfunction Score (GIDS)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Citrulline and intestinal fatty acid-binding protein (I-FABP) measurements
Number of subjects: 540
Study: 34359014

Group type: EXPERIMENTAL
Intervention: Pediatric amygdala and hippocampus volume
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Subcortical shape analysis
Number of subjects: 81

Group type: COMPARATOR
Intervention: Striatal anatomy
Number of subjects: 81
Study: 34359048

Group type: EXPERIMENTAL
Intervention: SIACI of bevacizumab (15 mg/kg) and cetuximab (200 mg/m2)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SIACI of bevacizumab and cetuximab
Number of subjects: 13
Study: 34360133

Group type: EXPERIMENTAL
Intervention: Multi-sensor bracelets collecting passive data (acceleration, electrodermal activity, blood volume pulse) and active data via smartphone questionnaires.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy control couples (not specified intervention).
Number of subjects: 60
Study: 34360156

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccines (including booster doses)
Number of subjects: 0
Study: 34360198

Group type: EXPERIMENTAL
Intervention: Lower cortisol reactivity percentile (<25th)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Low CRF and high BP
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Black ethnicity
Number of subjects: 551
Study: 34360513

Group type: EXPERIMENTAL
Intervention: High maternal physical activity (PA)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Low maternal physical activity (PA)
Number of subjects: 223
Study: 34361902

Group type: EXPERIMENTAL
Intervention: Nutritional supplements and exercise training
Number of subjects: 0
Study: 34362196

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34362217

Group type: EXPERIMENTAL
Intervention: Systemic vulnerability biomarkers (Hs-CRP, MMP-9, IL-6, I-CAM, V-CAM, E-selectin) measured at 1 hour after revascularization
Number of subjects: 225
Study: 34362310

Group type: EXPERIMENTAL
Intervention: Community-based ART delivery (CAD) model
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Multi-month dispensing (MMD)
Number of subjects: 2000
Study: 34362415

Group type: EXPERIMENTAL
Intervention: Mechanical Power (MP)
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Driving Pressure (ΔP)
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Increasing quartiles of Mechanical Power (MP)
Number of subjects: 825
Study: 34362494

Group type: EXPERIMENTAL
Intervention: C-CAR011 infusion following lympho-depletion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: C-CAR011 infusion
Number of subjects: 6
Study: 34363189

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clarithromycin (started within first 5 days from symptoms onset)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clarithromycin (started later than 5 days from symptoms onset)
Number of subjects: 90
Study: 34363393

Group type: EXPERIMENTAL
Intervention: Workplace environment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Loss of meaning
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Communication issues
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Daily interactions
Number of subjects: 45
Study: 34363598

Group type: EXPERIMENTAL
Intervention: Current therapy and clinical practices for PDN
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG)
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD)
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Opium therapies
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Contradiction of first-line guideline recommendation for pain relief
Number of subjects: 1547

Group type: EXPERIMENTAL
Intervention: Contradiction of second-line guideline recommendation for opium dosage form
Number of subjects: 1547
Study: 34363769

Group type: EXPERIMENTAL
Intervention: Parenteral low-molecular-weight or unfractionated heparin for 72 hours followed by oral dabigatran 150 mg twice per day
Number of subjects: 402
Study: 34364096

Group type: EXPERIMENTAL
Intervention: FilmArray Pneumonia Panel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advice for rational use of FilmArray Pneumonia Panel
Number of subjects: 0
Study: 34364311

Group type: EXPERIMENTAL
Intervention: COVID-19 infection
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccination
Number of subjects: 32

Group type: COMPARATOR
Intervention: Uninfected, non-vaccinated controls
Number of subjects: 32
Study: 34364365

Group type: EXPERIMENTAL
Intervention: Transcranial color-coded duplex sonography assessment of cerebrovascular reactivity to carbon dioxide
Number of subjects: 30
Study: 34364384

Group type: EXPERIMENTAL
Intervention: Mentor mothers providing psychosocial and other support as a PMTCT intervention.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Mentor mothers as relatable role models for WLHIV.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Mentor mothers' services delivery preference.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Mentor mother needs identified.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Overall acceptability of mentor mothers as a PMTCT intervention.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Challenges faced by mentor mothers and clients.
Number of subjects: 118
Study: 34364652

Group type: EXPERIMENTAL
Intervention: PATH checklist
Number of subjects: 587
Study: 34364770

Group type: EXPERIMENTAL
Intervention: Fenestrated/branched endografts (F/BEVAR)
Number of subjects: 85
Study: 34365516

Group type: EXPERIMENTAL
Intervention: CD19 CAR-T therapy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: CD19 CAR-T therapy with consolidative allo-HSCT
Number of subjects: 254
Study: 34365644

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg (twice daily)
Number of subjects: 7250
Study: 34365799

Group type: EXPERIMENTAL
Intervention: Transmethylamine-N-Oxide (TMAO) levels
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction
Number of subjects: 195
Study: 34365878

Group type: EXPERIMENTAL
Intervention: KA2237, a dual p110β/p110δ inhibitor, administered orally.
Number of subjects: 21
Study: 34366107

Group type: EXPERIMENTAL
Intervention: Keratinocyte-fibroblast interactions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34366147

Group type: EXPERIMENTAL
Intervention: Cellular senescence
Number of subjects: 0
Study: 34366734

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marine omega-3 (n-3) fatty acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 34366804

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Control Training (CCT)
Number of subjects: 0
Study: 34366928

Group type: EXPERIMENTAL
Intervention: CNS stimulants (predominantly OROS-Methylphenidate, up to 54 mg per day)
Number of subjects: 0
Study: 34367149

Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation (haplo SCT) and dinutuximab (anti-GD2 antibody)
Number of subjects: 0
Study: 34367680

Group type: EXPERIMENTAL
Intervention: Canakinumab treatment for cytokine release syndrome (CRS) in COVID-19-induced pneumonia
Number of subjects: 51
Study: 34367728

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (HDC)
Number of subjects: 84
Study: 34368242

Group type: EXPERIMENTAL
Intervention: Cardiac Shock Wave Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34368249

Group type: EXPERIMENTAL
Intervention: Elevated Serum Levels of Soluble ST2
Number of subjects: 0
Study: 34368662

Group type: EXPERIMENTAL
Intervention: Co-infection with intestinal parasites
Number of subjects: 0

Group type: COMPARATOR
Intervention: No co-infection with intestinal parasites
Number of subjects: 0
Study: 34369075

Group type: EXPERIMENTAL
Intervention: Breastmilk feeding
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Continuous EBF for at least 3 months
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Feeding category transitions
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Supplemental formula use
Number of subjects: 151
Study: 34369165

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 5006

Group type: COMPARATOR
Intervention: LDL-C cohort
Number of subjects: 5006

Group type: COMPARATOR
Intervention: Younger patients
Number of subjects: 5006

Group type: COMPARATOR
Intervention: Men
Number of subjects: 5006

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 5006

Group type: COMPARATOR
Intervention: Education
Number of subjects: 5006
Study: 34369187

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C) level
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Inflammation defined by hs-CRP level of ≥1.0 mg/L
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Overall incidence of primary outcome
Number of subjects: 1864
Study: 34369198

Group type: EXPERIMENTAL
Intervention: Cardio-Ankle Vascular Index (CAVI)
Number of subjects: 2932

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2932
Study: 34369333

Group type: COMPARATOR
Intervention: CON (25 g whey protein hydrolysate)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LOW (25 g whey protein hydrolysate + 3179 mg Capolac®)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MED (25 g whey protein hydrolysate + 6363 mg Capolac®)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HIGH (25 g whey protein hydrolysate + 9547 mg Capolac®)
Number of subjects: 18
Study: 34369385

Group type: EXPERIMENTAL
Intervention: Lunch meal in IS subjects
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dinner meal in IR subjects
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nocturnal and next-morning hyperlipidemia in IR subjects
Number of subjects: 16
Study: 34369388

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy-weight controls
Number of subjects: 31
Study: 34369413

Group type: EXPERIMENTAL
Intervention: Thromboelastography assay (TEG-6s)
Number of subjects: 119
Study: 34369416

Group type: EXPERIMENTAL
Intervention: p.Pro51Ser (p.P51S) variant carriers
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Conventional hearing aids (PTA ≥ 40 dB HL)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cochlear implants (PTA ≥ 70 dB HL)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Interaural asymmetry and variability assessment
Number of subjects: 111
Study: 34369417

Group type: EXPERIMENTAL
Intervention: C-VEMP activity
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Caloric responses (water irrigation)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: vHIT VOR-gains
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Hearing deterioration in female carriers
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: VNG caloric gain (water irrigation)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Three SCCs
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Loss of C-VEMP response
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Vestibular decline preceding hearing deterioration
Number of subjects: 111
Study: 34369424

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (MPA) 150-mg intramuscular injection
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Efavirenz-based HIV therapy and rifampicin plus isoniazid
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exploratory analyses of 28 polymorphisms in 14 genes
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Depot MPA dosing frequency
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CYP2B6 metabolizer or NAT2 acetylator status
Number of subjects: 62
Study: 34369447

Group type: EXPERIMENTAL
Intervention: PwS walking over a computerized treadmill system at self-selected speed
Number of subjects: 22
Study: 34369451

Group type: EXPERIMENTAL
Intervention: Physical activity measured using Actigraph GT3x accelerometer, average 5876 ± 3180 steps per day.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Female gender, being 70 years of age and older, and greater reported mobility problems.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pandemic-related reduction in exercise habits and rehabilitation attendance.
Number of subjects: 89
Study: 34369983

Group type: EXPERIMENTAL
Intervention: Ocular surface microbiome sequencing using whole-metagenome shotgun sequencing and tear proteome identification using chromatography tandem mass spectrometry.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ocular surface microbiome
Number of subjects: 20